Lilly's Jaypirca (Pirtobrutinib) Met Its Primary Endpoint in First-of-Its-Kind, Head-to-Head Phase 3 Study versus Imbruvica (Ibrutinib)

Evidence grows for pirtobrutinib as a safer and effective alternative for CLL and SLL

Pirtobrutinib, a non-covalent Bruton tyrosine kinase (BTK) inhibitor, met the primary endpoint for non-inferiority in terms of overall response rate in the first head-to-head comparison with ibrutinib, a covalent BTK inhibitor.

Lilly's Jaypirca (pirtobrutinib) met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica (ibrutinib)

In addition to meeting the primary endpoint of non-inferiority for overall response rate (ORR) in the BRUIN CLL-314 study, pirtobrutinib achieved a numerically higher ORR of 87.0% compared to 78.5% for ibrutinib in the intent-to-treat (ITT) population

At ASH, Lilly makes case to widen Jaypirca use in leukemia, lymphoma

In a head-to-head trial, Lilly’s drug was as effective as Imbruvica at inducing responses and displayed certain safety advantages that could make it a preferred treatment in early lines of care.

Pirtobrutinib Demonstrates Noninferior ORR, PFS Benefit Trend in CLL

Pirtobrutinib demonstrated noninferior response rates to ibrutinib and showed a trend toward survival benefit in patients with CLL/SLL.

Eli Lilly reports Phase III trial results of Jaypirca for CLL/SLL

Eli Lilly and Company has reported the outcomes from the Phase III BRUIN CLL-314 trial of Jaypirca, a non-covalent BTK inhibitor, against Imbruvica for CLL/SLL.The post Eli Lilly reports Phase III trial results of Jaypirca for CLL/SLL appeared first on Clinical Trials Arena.

Jaypirca Matches Imbruvica's Effectiveness for CLL, With Hints of Long-Term Benefit

A clinical trial found that Jaypirca was more effective than Imbruvica across the frontline and relapsed/refractory CLL/SLL settings.